Who
Jennifer E. Cook
Director
Company insider
Files Form 4 as: Director, Jazz Pharmaceuticals; Director, BridgeBio Pharma; Director, Denali Therapeutics.
In numbers
- Trades disclosed
- 97
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $44.4M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 6 Nov 2018
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $3,41714 at $244.06 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $408K1,692 at $241.39 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $3,41714 at $244.06 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $408K1,692 at $241.39 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $161K19,000 at $8.45 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $3.3M112,422 at $29.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $288K17,167 at $16.75 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,000 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —112,422 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,167 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $3.0M36,167 at $84.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $10.1M112,422 at $90.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,000 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —112,422 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,167 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $161K19,000 at $8.45 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $3.3M112,422 at $29.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $288K17,167 at $16.75 | filing |
News
BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BBIO · manilatimes.net · 16 Oct 2026
0 headlines in the last 90 days name Jennifer E. Cook; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.